Merck’s Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?

Merck's Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?

5 questions ESMO cancer drug data might answer

5 questions ESMO cancer drug data might answer

Roche’s Tecentriq extends its hot streak with liver cancer combo breakthrough

    Roche’s Tecentriq is on a much-needed hot streak. On Tuesday, the immuno-oncology drug—in combination with Roche’s Avastin—picked up a breakthrough therapy designation from the FDA in previously untreated liver cancer patients, putting it on the path to a speedy approval. The agency based the decision on phase 1b data, presented at last month’s American … Συνεχίστε να διαβάζετε Roche’s Tecentriq extends its hot streak with liver cancer combo breakthrough.